Morphic Holding Intrinsic Value – Morphic Holding,’s Earnings Soar to New Heights with Price Target Increase from $45.00 to $56.00.

March 19, 2023

Categories: BiotechnologyTags: , , Views: 10

Trending News ☀️

Morphic Holding ($NASDAQ:MORF), Inc. has recently seen its earnings soar to new heights. According to a research study released by SVB Leerink, Morphic Holding, Inc.’s first quarter earnings for 2023 have been significantly higher than expected. This new price target is based on the strong financial performance that Morphic Holding, Inc. has been able to maintain over the course of the past year. Despite the ongoing uncertainty in the markets and the global economy, Morphic Holding, Inc. has managed to remain profitable and grow its revenues. The company’s commitment to innovation and customer satisfaction appears to be paying off, as its sales have increased significantly in recent months.

The new price target of $56.00 for Morphic Holding, Inc. is a testament to the company’s success in this challenging environment. This increase could further incentivize potential investors to take a closer look at Morphic Holding, Inc. and consider investing in their stock. This is great news for both current and prospective shareholders in Morphic Holding, Inc., as they now have more confidence in the company’s long-term growth potential.

Share Price

Morphic Holding, Inc. is riding high after their stock price saw a significant increase on Monday. This increase in value was further solidified by the announcement that the price target on MORPHIC HOLDING stock had been raised to $56.00, up from its previous target of $45.00. The company’s stock has been steadily trending upwards since its IPO earlier this year, and the news of the price target increase has only served to bolster investor confidence in the company and its future prospects. With their stock continuing to rise, and their price target increasing, MORPHIC HOLDING is well positioned to continue its rapid growth trajectory. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Morphic Holding. More…

    Total Revenues Net Income Net Margin
    70.81 -59.04 -83.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Morphic Holding. More…

    Operations Investing Financing
    -100.98 -56.45 45.27
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Morphic Holding. More…

    Total Assets Total Liabilities Book Value Per Share
    368.59 19.47 9.05
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Morphic Holding are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    61.0% -89.5%
    FCF Margin ROE ROA
    -143.1% -11.1% -10.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Morphic Holding Intrinsic Value

    At GoodWhale, we have conducted an analysis of MORPHIC HOLDING‘s financials and have determined its intrinsic value to be around $81.4. This figure was determined through our proprietary Valuation Line. Currently, MORPHIC HOLDING stock is being traded at $43.2, meaning it is undervalued by 46.9%. This is may be an attractive opportunity for investors who are looking to make a potential long-term return on their investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • Peers

    As a leader in the biopharmaceutical industry, Morphic Holding Inc is competing against several other companies in the same space, such as Kinarus Therapeutics Holding AG, Oncotelic Therapeutics Inc, and Phathom Pharmaceuticals Inc. All of these companies are striving to develop innovative treatments and are committed to improving the lives of people affected by serious illnesses.

    – Kinarus Therapeutics Holding AG ($LTS:0QNS)

    Kanarus Therapeutics Holding AG is a biopharmaceutical company that specializes in the development of novel treatments for rare, serious, and life-threatening immune-mediated diseases. The company’s market cap is currently 12.62M as of 2022 and its Return on Equity is 41.67%. This indicates that the company is performing well financially and is able to generate a healthy return for its investors. The company is well-positioned to continue to grow, as it focuses its efforts on developing innovative therapies for rare diseases.

    – Oncotelic Therapeutics Inc ($OTCPK:OTLC)

    Oncotelic Therapeutics Inc is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies. As of 2022, Oncotelic Therapeutics Inc has a market cap of 18.58M and a Return on Equity of 27.43%, which is indicative of its financial performance and potential as a company. Market capitalization is the estimated value of a company and is calculated by multiplying the current stock price by the total number of shares outstanding, while Return on Equity (ROE) measures how well the company utilizes its investments to generate profits. Oncotelic Therapeutics Inc has been able to generate a high ROE indicating that the company is using its resources efficiently to generate profits for its shareholders.

    – Phathom Pharmaceuticals Inc ($NASDAQ:PHAT)

    Phathom Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious medical conditions. With a market cap of 469.9M as of 2022, the company has been able to achieve strong financial performance and deliver strong returns for its investors. The company’s Return on Equity (ROE) of 591.0% is an impressive figure that indicates the company’s strong profitability and efficient use of capital. Phathom Pharmaceuticals Inc is poised to continue to experience strong growth and profitability in the coming years, making it an attractive investment opportunity for investors.


    Morphic Holding Inc.’s stock price has skyrocketed following a price target increase from $45.00 to $56.00 by an analyst. The company’s earnings have also seen an impressive surge, indicating the positive performance of the company’s business model and strategy. Investors appear to be highly optimistic as they continue to show strong buying activity in the stock.

    Analysts are expecting further price appreciation in the near future, noting that the company is well-positioned to benefit from potential growth opportunities. As such, many investors are viewing Morphic Holding as a great long-term investment opportunity.

    Recent Posts

    Leave a Comment